Join us on Friday, May 15, from 2:30–3:15 pm at the Science & Technology Hall Product Theater Booth #2701
Presentation by Mark Fallick, MD, MBA, FACS
Urologist, Senior Medical Director, Radioligand Therapy
Novartis Pharmaceuticals Corporation
Session Contents:
- Overview of imaging modalities in prostate cancer with a focus on PET/CT
- Radioligand imaging in prostate cancer, its mechanism of action, and uses based on current guidelines and consensus
Impact of PSMA PET on staging of prostate cancer and management of biochemically recurrent disease, hormone-sensitive and castration-resistant prostate cancer
